Shattuck Labs, Inc. STTK
Shattuck Labs, Inc. (Nasdaq: STTK) is an immunology/inflammation drug developer. Its lead program, SL-325, is in Phase 1 for Inflammatory bowel disease (Crohn's disease Phase 2b planned). Its next catalyst on record is SL-846: Additional preclinical data including NHP toxicology (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SL-846 — Additional preclinical data including NHP toxicology (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SL-325 | Crohn's disease (RECEPTIVE-CD1 Phase 2b, ~232 patients); Phase 1 SAD/MAD in healthy volunteers completed | antibody | Phase 1 |
| SL-846 | Inflammatory and immune-mediated disease (DR3/IL-23R bispecific) | antibody | Pre-clinical |
| SL-425 | DR3-targeted asset | antibody | Pre-clinical |
Recent results and decisions
- Jun 9, 2026positive SL-325 Phase 1 in healthy participants: well tolerated across 0.1-30 mg/kg, no DR3 agonism, ~16-day half-life, ADA rate 3.7% (2/54), TL1A blockade lasting months supporting quarterly dosing.
Well tolerated across all dose levels, with a safety profile similar to those reported for anti-TL1A mAbs
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.